RT Book, Section
A1 Wee, Jon O.
A2 Sugarbaker, David J.
A2 Bueno, Raphael
A2 Colson, Yolonda L.
A2 Jaklitsch, Michael T.
A2 Krasna, Mark J.
A2 Mentzer, Steven J.
A2 Williams, Marcia
A2 Adams, Ann
SR Print(0)
ID 1105842994
T1 Nonoperative Treatments For Lung Cancer Percutaneous Thoracic Tumor Ablation
T2 Adult Chest Surgery, 2e
YR 2015
FD 2015
PB McGraw-Hill Education
PP New York, NY
SN 978-0-07-178189-3
LK accesssurgery.mhmedical.com/content.aspx?aid=1105842994
RD 2021/03/02
AB Lung  cancer  remains  the  leading  cause  of  cancer  death  for  both  men  and  women.1  Only  one-third  of  patients  diagnosed  with  lung  cancer  are  stage  appropriate  for  surgical  therapy.  In  addition,  the  rising  population  of  elders  in  the  United  States  and  other  Western  countries  has  caused  an  increase  in  the  number  of  patients  with  comorbidities,  making  primary  surgical  and  curative  therapy  more  complicated.  In  fact,  a  review  of  the  California  cancer  registry  revealed  that  stage  I  cancer  patients  who  received  no  treatment  have  a  median  survival  of  9  months.  Eighty-nine  percent  of  patients  who  were  recommended  for  treatment  but  refused  died  within  5  years,  and  78%  of  these  patients  died  from  cancer-specific  causes.  For  T1  lesions,  the  survival  rate  for  treated  cancers  was  155  months  versus  26  months  for  untreated  cancers.2  For  those  patients  treated  with  conventional  external  radiation  alone,  5-year  survival  is  10%  to  30%.3  Hence,  appropriate  treatment  even  for  patients  with  major  comorbidities  should  be  available.